Beam Therapeutics Inc. (Nasdaq: BEAM) has reported initial clinical data from its Phase 1/2 trial of BEAM-301, an investigational base-editing treatment for glycogen storage disease type Ia, or GSDIa.
The October 27 update included six patients as of the August 17 data cutoff. Three received a 20-milligram dose and three received 40 milligrams, with median follow-up of 7.6 months.
BEAM-301 uses a liver-targeting lipid nanoparticle to deliver base-editing reagents designed to correct the R83C mutation in the G6PC1 gene. That mutation disrupts the body’s ability to maintain blood glucose during fasting, requiring patients to consume raw cornstarch frequently to reduce the risk of severe hypoglycemia.
In the 40-milligram cohort, median time to fasting hypoglycemia increased from 2.5 hours at baseline to the protocol maximum of 15 hours at Day 36. Two of the three patients reached 15 hours and had stopped daily starch supplementation at their latest reported assessments.
The third patient in that cohort did not improve at the first post-treatment assessment. Beam said elevated body mass index and the patient’s genetic profile may have contributed, although that explanation has not been established.
Results were more modest at the lower dose. Median time to hypoglycemia in the 20-milligram group increased from 2.9 hours at baseline to 4.3 hours at Day 36.
“The promise of base editing is to deliver transformative outcomes that correct the root cause of disease with a one-time therapy,” CEO John Evans said.
Safety findings remain important. All six patients experienced at least one treatment-related adverse event, while four experienced a serious treatment-related event. These included three Grade 3 infusion reactions. Serious events of diarrhea and rhabdomyolysis were also reported in two patients, and all resolved.
No dose-limiting toxicities, Grade 4 or Grade 5 treatment-emergent adverse events, or treatment discontinuations were reported. Beam has modified its steroid premedication and infusion-rate procedures following the infusion reactions.
The findings are preliminary. The study is open-label, includes only six patients and has no control group. Longer follow-up and data from additional participants will be required to evaluate durability, safety and the consistency of the apparent treatment effect.
BEAM-301 is also entering a changing treatment market. The FDA granted accelerated approval to Ultragenyx’s Genglycos in August 2026 for patients aged eight and older with GSDIa. Genglycos is an AAV-based gene therapy, while BEAM-301 is intended to correct a specific disease-causing mutation through base editing.
Beam reported approximately $1.2 billion in cash, cash equivalents and marketable securities as of June 30, 2026. Its second-quarter net loss was $122.7 million. The company projects that its available capital, together with an expected $200 million credit-facility draw, can support operations into mid-2029.
Upcoming Catalysts
- Enrollment and initial results from the 60-milligram cohort
- Longer follow-up from the first six treated patients
- FDA discussions regarding a potential development and approval path
- Additional safety data following changes to infusion procedures
- Details about dose expansion and subsequent trial design
Sources
- Beam Therapeutics reports initial BEAM-301 clinical data — October 27, 2026
- BEAM-301 Phase 1/2 trial record — ClinicalTrials.gov
- Beam Therapeutics second-quarter 2026 results — SEC
- Beam Therapeutics Form 10-Q for the quarter ended June 30, 2026 — SEC
- FDA approves Genglycos for GSDIa — August 19, 2026
Editorial Disclosure
This article is based entirely on publicly available information, including company announcements, SEC filings, the federal clinical-trial registry and FDA materials. Securities discussed or referenced include Beam Therapeutics Inc. (Nasdaq: BEAM) and Ultragenyx Pharmaceutical Inc. (Nasdaq: RARE). Biotech Stocks Daily has not received compensation from any company mentioned, its management, investor relations representatives or any third party for this specific article. Biotech Stocks Daily may have current or past paid business relationships with other companies, which do not influence the content or conclusions of this article. No staff member or principal of Biotech Stocks Daily holds a position in any security mentioned at the time of publication.
Sources used include Beam Therapeutics’ October 27, 2026 clinical-data announcement, ClinicalTrials.gov, Beam’s second-quarter financial results and Form 10-Q, and the FDA’s August 19, 2026 announcement concerning Genglycos. Information about BEAM-301’s mechanism and preliminary clinical performance originated primarily from Beam and has not been independently validated by Biotech Stocks Daily.
BEAM-301 remains investigational and has not been approved by the FDA or another regulatory authority. The reported results involve six patients in an uncontrolled, open-label study and may not predict outcomes in a larger trial. Four patients experienced serious treatment-related adverse events. Additional risks include adverse events, limited durability, inconsistent efficacy, regulatory delays and failure to demonstrate a favorable benefit-risk profile.
Financial information reflects Beam’s position as of June 30, 2026. The company reported substantial operating losses and expects continued losses and negative operating cash flow. Its projected runway into mid-2029 incorporates an expected $200 million credit-facility draw and is a forward-looking estimate that may change.
Biotechnology securities are speculative investments carrying significant risk, including the potential total loss of capital. Coverage on Biotech Stocks Daily is provided for informational and educational purposes only. Biotech Stocks Daily is not a registered investment advisor. Nothing in this article constitutes financial, investment or professional advice. Readers are encouraged to conduct their own due diligence and consult a qualified financial advisor before making investment decisions. For more information, please see our full DISCLAIMER.
